The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

This study is testing whether adding camrelizumab (an immunotherapy drug) before and after standard chemoradiation therapy improves outcomes for people with locally advanced head and neck squamous cell carcinoma (HNSCC) — cancers of the mouth, throat, voice box, or nasal passages that cannot be surgically removed. **You may be eligible if...** - You are 18 years old or older - You have a confirmed diagnosis of squamous cell carcinoma of the lip, oral cavity, throat (oropharynx or hypopharynx), voice box, or nasal sinus - Your cancer is stage III, IVa, or IVb (or stage III for HPV-positive throat cancer) - You cannot have surgery or have declined it, but are eligible for chemoradiation - Your tumor can be measured on CT or MRI scan - You have adequate blood counts and organ function **You may NOT be eligible if...** - You have had prior immunotherapy treatment (PD-1, PD-L1, or CTLA-4 drugs) - You have an active autoimmune disease requiring treatment - You have active hepatitis B or C - You are pregnant or breastfeeding - You have a history of immunodeficiency or organ transplantation Talk to your doctor to see if this trial is right for you.